S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD
OncLive® On Air - Podcast tekijän mukaan OncLive® On Air
Dr Arbour discusses the mechanisms of action of zoldonrasib and daraxonrasib and shares early data with these agents in RAS-mutant NSCLC.
